🇺🇸 FDA
Pipeline program

CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN

MK-3475-06C

Phase 2 small_molecule active

Quick answer

CALCIUM FOLINATE , MK-2870, -, -, PARACETAMOL , MK-1022, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CALCIUM LEVOFOLINATE , CAPECITABINE , -, MK-2870, FLUOROURACIL , OXALIPLATIN for Gastroesophageal cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Gastroesophageal cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials